Rapid alternation of drug therapy is highly efficient in suppressing the emergence of mutant drug-resistant HIV strains in cell culture

AIDS Research and Human Retroviruses

Volumn 17, Issue 17, 2001, Pages 1625-1634

  Balzarini, Jan ^a   De Clercq, E ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

LAMIVUDINE; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE;

ANIMAL CELL; ARTICLE; CELL CULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MUTATION; NONHUMAN; PRIORITY JOURNAL; VIRUS MUTANT; VIRUS REPLICATION; VIRUS RESISTANCE; VIRUS STRAIN;

ANTI-HIV AGENTS; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 0035695372     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/088922201753342031     Document Type: Article

References (14)

1. Changing treatment strategies and goals
2. Multiple drug resistance to nucleoside analogues and nonnucleoside reverse transcriptase inhibitors in an efficiently replicating human immunodeficiency virus type 1 patient strain
3. Multiple dideoxynucleoside analogue-resistant (MddNR) HIV-1 strains isolated from patients from different European countries
4. Anti-human immunodeficiency virus drug combination strategies
5. Decay characteristics of HIV-1-infected compartments during combination therapy
6. Viral dynamics of HIV: Implications for drug development and therapeutic strategies
7. Human immunodeficiency virus replication and genotypic resistance in blood and lymph nodes after a year of potent antiretroviral therapy
8. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy
9. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy
10. Mutations in HIV-1 reverse transcriptase and protease associated with drug resistance
11. RNA virus fitness
12. Results at 9 months of follow-up
13. Concomitant combination therapy for HIV infection preferable over sequential therapy with 3TC and non-nucleoside reverse transcriptase inhibitors
14. Marked inhibitory activity of non-nucleoside reverse transcriptase inhibitors against human immunodeficiency virus type 1 when combined with (-)2′,3′-dideoxy-3′-thiacytidine